Vaxart (OTCMKTS:VXRT) Announces Quarterly Earnings Results

Vaxart (OTCMKTS:VXRT) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.04), Zacks reports. Vaxart had a return on equity of 53.04% and a net margin of 15.88%.

Vaxart Trading Down 7.5%

Shares of OTCMKTS VXRT traded down $0.03 during midday trading on Thursday, reaching $0.37. 434,774 shares of the stock were exchanged, compared to its average volume of 288,712. The company has a market capitalization of $90.17 million, a P/E ratio of 2.50 and a beta of 1.15. Vaxart has a 52-week low of $0.33 and a 52-week high of $0.84. The stock has a 50 day moving average price of $0.46 and a 200-day moving average price of $0.58.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Vaxart to a “hold” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, Vaxart presently has a consensus rating of “Hold”.

Vaxart Company Profile

Vaxart, Inc is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.

Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza.